Eskild A
Avdeling for Samfunnsmedisin Statens Institutt for Folkehelse, Oslo.
Tidsskr Nor Laegeforen. 1994 Jun 20;114(16):1840-4.
The benefit of the BCG mass-vaccination program has not been widely questioned in Norway, ever though corresponding programmes have been discontinued in Sweden and Denmark. Today, the risk of becoming infected with Mycobacterium tuberculosis is very low in Norway, and effective treatment is available. However, it is uncertain how Norway will be affected by the increasing incidence of tuberculosis in other countries. The efficacy of the BCG-vaccine is controversial, and widespread use of the vaccine makes it impossible to use the Pirquet-test as a tool in diagnosis. It is necessary to evaluate the BCG-program critically. Better education of physicians in diagnostic and preventive measures may be a more appropriate way of controlling tuberculosis than mass-vaccination.
尽管瑞典和丹麦已停止相应计划，但卡介苗大规模接种计划在挪威的益处尚未受到广泛质疑。如今，挪威感染结核分枝杆菌的风险非常低，且有有效的治疗方法。然而，尚不确定挪威将如何受到其他国家结核病发病率上升的影响。卡介苗的功效存在争议，该疫苗的广泛使用使得不可能将结核菌素试验用作诊断工具。有必要对卡介苗计划进行严格评估。相比大规模接种，对医生进行更好的诊断和预防措施教育可能是控制结核病更合适的方法。
